Example report. The whole genome example: a public genome from the 1000 Genomes Project, with CYP2D6 Structural Analysis, so you can see what yours will look like. Get your own report

PsychostimulantsExample report

Atomoxetine

Strattera

Use with caution

Your body clears this medicine very quickly, so you may need a higher dose to get the right effect.

The genes behind this label

The guidelines read one gene for atomoxetine. Each card shows the two copies this person inherited and what they mean.

CYP2D6*2/*2x2

Ultrarapid metabolizer

One copy works normally and one works faster than usual.

3.0 activity scoreTypical: 1.25 to 2.25

Turns on or clears about 1 in 4 prescription drugs. These include many drugs for depression, pain and ADHD.

This result changes the label.

What the guidelines say

What each guideline says about your result.

CYP2D6Ultrarapid metabolizer

CPIC guideline

Use with caution Evidence: moderateRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)

In plain words: Your body clears this medicine very quickly, so you may need a higher dose to get the right effect.
What it means: Based on very limited data available for CYP2D6 ultrarapid metabolizers taking atomoxetine, it is unlikely ultrarapid metabolizers would achieve adequate serum concentrations for the intended effect at standard dosing.
What the guideline suggests: Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/ml, consider a proportional increase in dose to approach 400 ng/ml. Dosages greater than 100 mg/day may be needed to achieve target concentrations.

FDA drug label

Use as directed See the FDA table (U.S. Food and Drug Administration, opens in a new tab)

In plain words: Your CYP2D6 result means higher CYP2D6 activity than usual, but the FDA gives no genetic dosing change for atomoxetine at this result.
What it means: No FDA guidance for your genotype
What the label suggests: Initiate therapy with recommended starting dose.

About atomoxetine

Atomoxetine (Strattera) is a non-stimulant ADHD medicine for adults and children 6 and older.

Used for: Attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 and older

Others in psychostimulants

Compare all 2 psychostimulants

AmphetamineAdzenys ER Use as directed

Don't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.

Back to the example report